Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer

BEDFORD, Mass--(BUSINESS WIRE)--Oct. 20, 2016--
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced the appointment
of Andy Hurley to the newly created position of chief commercial
officer, effective immediately. In this role, Mr. Hurley will be
responsible for leading Ocular’s commercial organization, focusing on
effective execution of potential future product launches, brand
development, and ongoing commercialization strategies.

“Andy brings extensive commercial strategy and product launch expertise
as well as a proven ability to develop and lead commercialization
efforts globally,” said Amar Sawhney, Ph.D., President, Chief Executive
Officer and Chairman of Ocular Therapeutix. “Andy’s experience will be
extremely valuable as we continue to prepare for the potential launch of
our lead product candidate, DEXTENZA™, where our objective is to
maximize product uptake and revenue from the outset. If approved by the
FDA, we believe DEXTENZA would be the first extended release steroid
containing no preservatives available to ophthalmologists that would
provide the complete course of therapy with a single placement.”

Mr. Hurley has over two decades of sales, marketing, market access and
commercial operations experience across the pharmaceutical industry.
Most recently, Mr. Hurley served as Vice President, Sales and Marketing
at Dyax Corporation prior to its acquisition by Shire in January 2016.
In this role, Mr. Hurley led the strategic and tactical launch planning
for the launch of DX-2930, a product candidate under development for the
treatment of hereditary angioedema, or HAE. Prior to Dyax, Mr. Hurley
held several senior positions within Sunovion Pharmaceuticals, including
Vice President of Marketing and Vice President of Commercial Operations.
At Sunovion, he was responsible for leading all marketing activities for
its asthma franchise, including overall strategic planning, life cycle
strategy, advertising campaigns, and market research. He also led
commercial operations functions including sales training, relationship
marketing and sales operations. Earlier in his career, Mr. Hurley held
commercial operations and sales roles at NitroMed and Forest
Pharmaceuticals. Mr. Hurley has also held various consulting roles,
providing commercial strategy development and tactical support to the
biotech industry.

“I am excited to join Ocular Therapeutix at such an important juncture
for the Company as it prepares for the potential commercialization of
DEXTENZA,” stated Mr. Hurley. “I look forward to working with the world
class team at Ocular to launch and commercialize DEXTENZA as well as the
Company’s additional innovative, extended release product candidates
across diverse indications in ophthalmology.”

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix has submitted an NDA for
post-surgical pain for its lead product candidate, DEXTENZA™
(dexamethasone insert, extended release), which is in Phase 3 clinical
development for post-surgical ocular inflammation and pain and allergic
conjunctivitis, and in Phase 2 clinical development for dry eye disease.
OTX-TP (sustained release travoprost) is in Phase 3 clinical development
for glaucoma and ocular hypertension. Ocular Therapeutix is also
evaluating sustained-release injectable drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery. For
additional information about the Company, please visit www.ocutx.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans
and prospects for the Company including the development and regulatory
status of the Company’s product candidates, such as the Company’s
expectations and plans regarding regulatory submissions for and the
timing and conduct of clinical trials of DEXTENZA™ for post-surgical
ocular inflammation and pain, including our expectations regarding the
NDA filed with the FDA, DEXTENZA for the treatment of allergic
conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the
treatment of glaucoma and ocular hypertension, the potential utility of
any of the Company’s product candidates, potential commercialization of
the Company’s product candidates, the sufficiency of the Company’s cash
resources and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation and conduct of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some
point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.